Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial
Dolutegravir als Erst- oder Zweitlinientherapie für Kinder mit HIV: 240-Wochen-Follow-up der randomisierten ODYSSEY-Studie
Open Forum Infectious Diseases · 28.04.2026 · 13 (5)
DOI: 10.1093/ofid/ofag266 ↗Auf einen Blick
In der ODYSSEY-Studie war Dolutegravir über 240 Wochen wirksamer als der Standard of Care. Behandlungsversagen trat seltener auf; Sicherheitsdaten zeigten keine Auffälligkeiten.
Fragestellung
Ist Dolutegravir bei Kindern mit HIV als Erst- oder Zweitlinientherapie über 240 Wochen wirksamer und sicherer als der Standard of Care?
Methode
Randomisierte Studie; 240-Wochen-Follow-up; flexible parametrische Überlebensmodelle unter Berücksichtigung von Therapiewechseln; Sicherheitsanalyse nach Intention-to-treat.
Ergebnisse
792 Teilnehmende (392 DTG, 400 SOC). Bis Woche 240: Behandlungsversagen bei 74 unter DTG und 131 unter SOC; geschätzt 19 % vs. 34 %; Differenz −15 % (95 %-KI −21 bis −9); P < .001.
Schlussfolgerung der Autor:innen
Dolutegravir zeigte über 240 Wochen eine überlegene Wirksamkeit gegenüber dem Standard of Care bei Kindern, ohne Sicherheitsbedenken.
Kernaussagen
- Behandlungsversagen: 19 % unter DTG vs. 34 % unter SOC
- Differenz −15 % (95 %-KI −21 bis −9); P < .001
- Serious adverse events und grade ≥3 Ereignisse ähnlich in beiden Gruppen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Klinische Studie in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 05.05.2026. Verfasst von Hilda Angela Mujuru und 28 weiteren Autor:innen. Beteiligte Einrichtung: University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Penta Foundation, ViiV Healthcare, UK Medical Research Council.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
The World Health Organization recommends dolutegravir (DTG) as the anchor antiretroviral therapy (ART) drug for children with HIV.
Methods
The ODYSSEY randomized trial evaluated DTG-based ART vs non-DTG standard of care (SOC) over 96 weeks in children starting first-line ART or switching to second-line. Participant follow-up was extended to 240 weeks; ART in extended follow-up was per national guidelines. Flexible parametric survival models estimated the proportion of participants with treatment failure on randomized allocation, accounting for treatment switches through censoring and inverse probability of censoring weights. Adverse events were analyzed in the intention-to-treat population.
Results
ODYSSEY enrolled 792 participants (392 DTG, 400 SOC): 311 started first-line (SOC, 92% efavirenz) and 396 second-line (SOC, 98% ritonavir-boosted protease inhibitors). The median (range) age at enrollment was 11.4 years (0.1–18.0); weight was 28.7 kg (3.4–85.0); and 89% were from Africa. Median follow-up on randomized allocation was 286 weeks (IQR, 230–310) for DTG and 204 weeks (168–240) for SOC. Among SOC participants, 23% switched to DTG before 192 weeks, 65% before 240 weeks. By 240 weeks, 74 participants on DTG and 131 on SOC had treatment failure (estimated, 19% vs 34%; difference [DTG-SOC], −15%; 95% CI, −21% to −9%; P < .001). Treatment effects were similar between first- and second-line (P = .10). The proportions of participants with serious adverse events (52 DTG vs 53 SOC, P = .92) or grade ≥3 adverse events (98 DTG vs 121 SOC, P = .09) were similar by arm over 192 weeks.
Conclusions
DTG showed superior efficacy vs SOC over 240 weeks in children, with no safety concerns.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe.
- UCL Innovative Clinical Trials Unit (former MRC CTU at UCL), Institute of Clinical Trials and Methodology, University College London, London, UK.
- Baylor College of Medicine Children's Foundation Uganda, Kampala, Uganda.
- Joint Clinical Research Centre, Mbarara, Uganda.
- Joint Clinical Research Centre, Kampala, Uganda.
- Faculty of Health Sciences, Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
ORCID-Profile: Cissy Kityo, Grace Miriam Ahimbisibwe, Ebrahim Variava, Mark Cotton, Thanyawee Puthanakit, Robin Kobbe, Srini Bandi, Alasdair Bamford, Pablo Rojo, Diana M Gibb
Förderung
- Penta Foundation
- ViiV Healthcare
- UK Medical Research Council
- Mylan-Viatris
Zitieren
APA
Mujuru, H. A., White, E., Kekitiinwa, A. R., Lugemwa, A., Kityo, C., Violari, A., Ahimbisibwe, G. M., Variava, E., Archary, M., Cotton, M., Ounchanum, P., Puthanakit, T., Kanjanavanit, S., Ngampiyaskul, C., Kobbe, R., Bandi, S., Epalza, C., Bwakura-Dangarembizi, M., Bbuye, D., …, & Ford, D. (2026). Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial. Open Forum Infectious Diseases, 13(5). https://doi.org/10.1093/ofid/ofag266
Vancouver
Mujuru HA, White E, Kekitiinwa AR, Lugemwa A, Kityo C, Violari A, et al. Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial. Open Forum Infectious Diseases. 2026;13(5). doi:10.1093/ofid/ofag266
BibTeX
@article{Mujuru2026,
author = {Mujuru, Hilda Angela and White, Ellen and Kekitiinwa, Adeodata R and Lugemwa, Abbas and Kityo, Cissy and Violari, Avy and Ahimbisibwe, Grace Miriam and Variava, Ebrahim and Archary, Moherndran and Cotton, Mark and Ounchanum, Pradthana and Puthanakit, Thanyawee and Kanjanavanit, Suparat and Ngampiyaskul, Chaiwat and Kobbe, Robin and Bandi, Srini and Epalza, Cristina and Bwakura-Dangarembizi, Mutsawashe and Bbuye, Dickson and Kasozi, Mariam and Kaudha, Elizabeth and Cressey, Tim R and Giaquinto, Carlo and Jafta, Lungile and Bamford, Alasdair and Rojo, Pablo and Gibb, Diana M and Turkova, Anna and Ford, Deborah},
title = {Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial},
journal = {Open Forum Infectious Diseases},
year = {2026},
volume = {13},
number = {5},
doi = {10.1093/ofid/ofag266}
}
EUVIMED